Cephalon says expenses jumped 30% in Q1

Share this article:
Cephalon reported that selling, general and administrative expenses jumped 30% in the first quarter to $199 million on DTC for narcolepsy drug Provigil (modafinil) and the launch of cancer drug Treanda (bendamustine hydrochloride).
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

FDA reviews new painkiller

The candidate would be the first to put oxycodone and morphine in one capsule.

AbbVie's files all-oral HCV drug with FDA

AbbVie's all-oral HCV treatment filed off six Phase-III trials spanning 25 countries and 2,300 patients

Rumor: Pfizer offered to buy AstraZeneca

The rumored $101 billion bid would give Pfizer a foothold in imuno-oncology and diabetes.